Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis
The Oncologist · 01.10.2025 · 30 (10)
DOI: 10.1093/oncolo/oyaf337 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Oncologist, online erschienen am 27.10.2025. Verfasst von Douglas Dias E Silva und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Israelita Albert Einstein, São Paulo, Brazil. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors, Sarcoma, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Soft tissue sarcomas (STS) are a rare and diverse group of mesodermal-origin cancers with limited systemic treatment options in advanced-stage disease. Recent evidence suggests that combination therapies involving tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor receptor (VEGFR) and immune checkpoint inhibitors (ICIs) may enhance clinical outcomes.
Methods
We conducted a systematic review and meta-analysis. Databases were searched for prospective clinical trials evaluating ICIs and VEGFR-TKIs combination therapy in adults with advanced STS. Primary outcomes were objective response rating (ORR), overall survival (OS), and progression-free survival (PFS). A subgroup analysis was performed for alveolar soft part sarcoma (ASPS). We extracted the grade ≥3 adverse events (AE) as the safety outcomes of interest. Random-effects modeling was used for analysis, and continuous endpoints were pooled using the mean difference (MD) with a random effects model.
Results
Eight non-randomized phase II trials involving 332 patients were eligible. The pooled ORR was 33% (95% CI: 17%-49%) and median PFS was 7.1 months (95% CI: 5.5-8.6). In the ASPS subgroup, the ORR reached 73% (95% CI: 64%-82%). Grade ≥3 AEs occurred in 40% of patients, most commonly hypothyroidism, diarrhea, and elevated hepatic enzymes.
Conclusion
The combination of ICIs and TKIs demonstrated promising efficacy, particularly in ASPS, with outcomes favorable to the historical benchmarks. Future studies should incorporate biomarker-driven and histology-specific approaches to optimize patient selection and improve the outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Israelita Albert Einstein, São Paulo, Brazil.
- State University of Rio Grande do Norte, Mossoró, Brazil.
- Hospital do Servidor Público Estadual, São Paulo, Brazil.
- São Domingos-Hospital, São Luis, Brazil.
- Ceará Cancer Institute, Federal University of Ceará, Ceará, Brazil.
ORCID-Profile: Douglas Dias E Silva
Zitieren
APA
Dias E Silva, D., Pernomian, L. S., Fernandes, M., Lenzi, M. C., Gazzoni, G., Fonseca, A. C., Silveira, L., Beal, J. R., Junior, P. L. S. U., Moura, F., Garcia, R. J., & Pestana, R. C. (2025). Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis. The Oncologist, 30(10). https://doi.org/10.1093/oncolo/oyaf337
Vancouver
Dias E Silva D, Pernomian LS, Fernandes M, Lenzi MC, Gazzoni G, Fonseca AC, et al. Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis. The Oncologist. 2025;30(10). doi:10.1093/oncolo/oyaf337
BibTeX
@article{DiasESilva2025,
author = {Dias E Silva, Douglas and Pernomian, Laura Sambugaro and Fernandes, Matheus and Lenzi, Miguel Chaves and Gazzoni, Gabriela and Fonseca, Ana Caroline and Silveira, Lara and Beal, Juliana Rodrigues and Junior, Pedro Luiz Serrano Uson and Moura, Fernando and Garcia, Reynaldo Jesus and Pestana, Roberto Carmagnani},
title = {Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {10},
doi = {10.1093/oncolo/oyaf337}
}
EUVIMED